LCS
VRTX icon

Levin Capital Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Levin Capital Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,071
Closed -$448K – 277
2024
Q1 		$448K Sell
1,071
-550
-34% -$233K 0.04% 141
2023
Q4 		$660K Buy
+1,621
New +$599K 0.07% 116

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Levin Capital Strategies's VRTX Position: Q2 2024 in Review

Levin Capital Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 1,071 shares — an estimated $448K sold.

Levin Capital Strategies first reported a position in VRTX in Q4 2023 and held it in 2 quarters. The position peaked at $660K in Q4 2023. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Levin Capital Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Levin Capital Strategies sold 1,071 Vertex Pharmaceuticals shares in Q2 2024, an estimated $448K.
  • Levin Capital Strategies first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Levin Capital Strategies's Vertex Pharmaceuticals position peaked at $660K in Q4 2023.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Levin Capital Strategies's 13F filing for Q2 2024, filed 7 Aug 2024.